推荐产品
化驗
≥98% (HPLC)
形狀
powder
顏色
off-white
溶解度
DMSO: >10 mg/mL
儲存溫度
−20°C
SMILES 字串
COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O
InChI
1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-
InChI 密鑰
HVXBOLULGPECHP-WAYWQWQTSA-N
一般說明
考布他汀A4属于秋水仙碱类。
應用
考布他汀A4已被用于:
- 作为抗微管剂用于确定G2/M期异柠檬酸脱氢酶(IDH1和IDH2)蛋白的作用
- 评估联苯CA4衍生物在2D和3D癌细胞和非癌细胞模型中的的抗增生和促凋亡特性
- 作为微管抑制剂用于研究其对猪蛔虫L3幼虫的作用
生化/生理作用
Combretastatin A4是一种靶向肿瘤血管以抑制血管生成的血管分裂剂(VDA)。它在β-微管蛋白的秋水仙碱结合位点抑制微管蛋白聚合。它通过抑制人胃细胞中的AKT功能而具有抗肿瘤活性。被抑制的 AKT 激活引起细胞增殖下降,细胞周期停滞,在体外 迁移/侵袭和 体内 转移能力降低 。Combretastatin A4 是一种天然二苯乙烯类苯酚。
考布他汀A4是一种强效的微管靶向剂。
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類(WGK)
WGK 2
閃點(°F)
Not applicable
閃點(°C)
Not applicable
個人防護裝備
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
其他客户在看
Biochemical pharmacology, 84(5), 612-624 (2012-06-19)
Recent clinical data demonstrated that the vascular targeting agent Combretastatin-A4 phosphate (CA-4P) prolonged survival of patients with advanced anaplastic thyroid cancer without any adverse side effects. However, as a single agent CA-4 failed to reduce tumour growth in the murine
Journal of neurosurgery, 128(6), 1668-1673 (2017-07-29)
OBJECTIVE Temporal lobe epilepsy (TLE) is the most common type of pharmacoresistant focal epilepsy, for which anterior mesial temporal lobe resection (AMTLR) is a treatment option. Focal cortical dysplasia Type IIIa (FCD IIIa), a developmental lesion resulting from defects in
Surgery, 152(6), 1078-1087 (2012-11-20)
Anaplastic thyroid cancer (ATC) is an aggressive neoplasm for which a paucity of data exist about the relative role of operative procedures in disease management. The FACT trial was a randomized, controlled phase 2/3 trial assessing the safety and efficacy
Radiology, 264(2), 436-444 (2012-06-14)
To investigate the potential value of magnetic resonance (MR) elastography and diffusion-weighted (DW) MR imaging in the detection of microstructural changes of murine colon tumors during growth and antivascular treatment. The study was approved by the regional ethics committee for
Expert opinion on investigational drugs, 13(9), 1171-1182 (2004-08-28)
Combretastatin A4 phosphate (CA4P) represents the lead compound in a group of novel tubulin depolymerising agents being developed as vascular targeting agents (VTAs). VTAs are drugs that induce rapid and selective vascular dysfunction in tumours. CA4P is a water-soluble prodrug
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门